Sequence information
Variant position: 252 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 821 The length of the canonical sequence.
Location on the sequence:
VVENEYGSINHTYHLDVVER
S PHRPILQAGLPANASTVVGG
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human VVENEYGSINHTYHLDVVERS PHRPILQAGLPANASTVVGG
Mouse LVENEYGSINHTYHLDVVERS PHRPILQAGLPANASTVVGG
Chicken IVENQYGSINHTYHLDVVERS PHRPILQAGLPANASAVVGG
Xenopus laevis IVENEHGSINHTYHLDVIERS SHRPILQAGLPANTTAVVGG
Zebrafish LVENQYGSIDHTYTLDVVERS PHRPILQAGLPANVTVQVGQ
Drosophila KVCNAWGCIQFDFSVQINDRT RSAPIIV--VPQNQTVKVNG
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
22 – 821
Fibroblast growth factor receptor 2
Topological domain
22 – 377
Extracellular
Glycosylation
241 – 241
N-linked (GlcNAc...) asparagine
Glycosylation
265 – 265
N-linked (GlcNAc...) asparagine
Alternative sequence
250 – 361
Missing. In isoform 17.
Alternative sequence
250 – 254
ERSPH -> GSQGL. In isoform 8.
Mutagenesis
265 – 265
N -> Q. Reduced N-glycosylation. Reduced expression at the cell surface.
Literature citations
Analysis of phenotypic features and FGFR2 mutations in Apert syndrome.
Park W.-J.; Theda C.; Maestri N.E.; Meyers G.A.; Fryburg J.S.; Dufresne C.; Cohen M.M. Jr.; Jabs E.W.;
Am. J. Hum. Genet. 57:321-328(1995)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 249-313; VARIANTS APRS TRP-252 AND ARG-253;
Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast growth factor receptor-2 activation supports osteoblast differentiation.
Kaabeche K.; Lemonnier J.; Le Mee S.; Caverzasio J.; Marie P.J.;
J. Biol. Chem. 279:36259-36267(2004)
Cited for: FUNCTION IN OSTEOBLAST DIFFERENTIATION AND IN PHOSPHORYLATION OF CBL; INTERACTION WITH CBL; UBIQUITINATION; CHARACTERIZATION OF VARIANT APRS TRP-252;
Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.
Ibrahimi O.A.; Eliseenkova A.V.; Plotnikov A.N.; Yu K.; Ornitz D.M.; Mohammadi M.;
Proc. Natl. Acad. Sci. U.S.A. 98:7182-7187(2001)
Cited for: X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 147-366 OF VARIANTS APRS TRP-252 AND ARG-253 IN COMPLEX WITH FGF2;
Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome.
Wilkie A.O.M.; Slaney S.F.; Oldridge M.; Poole M.D.; Ashworth G.J.; Hockley A.D.; Hayward R.D.; David D.J.; Pulleyn L.J.; Rutland P.; Malcolm S.; Winter R.M.; Reardon W.;
Nat. Genet. 9:165-172(1995)
Cited for: VARIANTS APRS TRP-252 AND ARG-253;
Description of a new mutation and characterization of FGFR1, FGFR2, and FGFR3 mutations among Brazilian patients with syndromic craniosynostoses.
Passos-Bueno M.R.; Sertie A.L.; Richieri-Costa A.; Alonso L.G.; Zatz M.; Alonso N.; Brunoni D.; Ribeiro S.F.M.;
Am. J. Med. Genet. 78:237-241(1998)
Cited for: VARIANTS CS PHE-278; PRO-337; ARG-338; ARG-342; PHE-342 AND TYR-342; VARIANTS APRS TRP-252 AND ARG-253; VARIANT JWS PHE-278;
Two common mutations 934C to G and 937C to G of fibroblast growth factor receptor 2 (FGFR2) gene in Chinese patients with Apert syndrome.
Tsai F.-J.; Hwu W.-L.; Lin S.-P.; Chang J.-G.; Wang T.-R.; Tsai C.-H.;
Hum. Mutat. Suppl. 1:S18-S19(1998)
Cited for: VARIANTS APRS TRP-252 AND ARG-253;
Presence of the Apert canonical S252W FGFR2 mutation in a patient without severe syndactyly.
Passos-Bueno M.R.; Richieri-Costa A.; Sertie A.L.; Kneppers A.;
J. Med. Genet. 35:677-679(1998)
Cited for: VARIANT PS TRP-252;
Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis.
Kan S.-H.; Elanko N.; Johnson D.; Cornejo-Roldan L.R.; Cook J.; Reich E.W.; Tomkins S.; Verloes A.; Twigg S.R.F.; Rannan-Eliya S.; McDonald-McGinn D.M.; Zackai E.H.; Wall S.A.; Muenke M.; Wilkie A.O.M.;
Am. J. Hum. Genet. 70:472-486(2002)
Cited for: VARIANTS CS CYS-105; PRO-267; VAL-276; CYS-281; PRO-289; ARG-338; HIS-340; PHE-342; TRP-342; CYS-347; CYS-354; HIS-549 AND GLY-678; VARIANTS PS PHE-172; 252-PHE-SER-253; CYS-290; CYS-340; PRO-341; ARG-342; SER-342; CYS-375; GLY-565; ARG-641 AND GLU-663; VARIANTS APRS TRP-252 AND ARG-253; VARIANTS CS/PS PHE-278 AND TYR-342; VARIANT CRANIOSYNOSTOSIS ASN-659; VARIANTS THR-186 AND SER-315;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.